Ars Pharmaceuticals Inc 's ability to collect accounts receivable sequentially worsen to 3.41, pointing to a challenging and on top of that deteriorating business climate for the Major Pharmaceutical Preparations industry. Ars Pharmaceuticals Inc 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 107 days, from 106 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 429 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 2536 to 2692.

What is Receivable Turnover Ratio?
What is Ars Pharmaceuticals Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SPRY Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	86.42 %	208.09 %	210.06 %	4615.52 %	-
Y / Y Revenue Change	114.15 %	184.47 %	-67.56 %	1471.62 %	3043.4 %
Receivable Turnover Ratio (TTM)	3.41	3.43	3.5	7.22	10.36
SPRY's Total Ranking	# 2692	# 2536	# 2129	# 2171	#
Accounts Receivable average collection period days	107	107	104	51	35
Seq. Receivable Change	63.42 %	13.08 %	-30.46 %	45.07 %	170.08 %
Seq. Revenue Change	48.4 %	-19.25 %	-13.58 %	106.79 %	97.13 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 137
Healthcare Sector	# 430
Overall Market	# 2692

Receivable Turnover Ratio Statistics
High	Average	Low
21.29	9.16	3.43
(Mar 31 2025)		(Mar 31 2026)

SPRY Company Profile • Back to SPRY Efficiency Comparisons • Compare SPRY Receivables Turnover Ratio to its Competitors

Financial Statements
Ars Pharmaceuticals Inc 's Accounts Receivable	$ 47 Millions	Visit SPRY's Balance sheet
Ars Pharmaceuticals Inc 's Sales TTM	$ 117 Millions	Visit SPRY's Income Statement
Sources of SPRY's Revenues		Visit SPRY's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
SPRY's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
SPRY's Growth Rates	SPRY's Roa	SPRY's Inventory Turnover Ratio	SPRY's Dividend Comparisons
SPRY's Profitability Ratios	SPRY's Roi	SPRY's Asset Turnover Ratio	SPRY's Dividend Growth
SPRY's Valuation Ratios	SPRY's Roe	SPRY's Financial Strength Ratios	SPRY's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Nephros Inc	6.83	$ 21.686 Millions	$ 3.173 Millions
Medpace Holdings Inc	6.82	$ 2,782.288 Millions	$ 408.189 Millions
Opko Health Inc	6.79	$ 587.896 Millions	$ 86.589 Millions
Atara Biotherapeutics Inc	6.79	$ 6.452 Millions	$ 0.950 Millions
Rapid Micro Biosystems Inc	6.76	$ 34.545 Millions	$ 5.111 Millions
Universal Health Services Inc	6.75	$ 18,114.487 Millions	$ 2,683.492 Millions
3m Company	6.72	$ 25,180.000 Millions	$ 3,747.750 Millions
Phibro Animal Health Corporation	6.70	$ 1,516.861 Millions	$ 226.555 Millions
Eton Pharmaceuticals Inc	6.67	$ 105.279 Millions	$ 15.783 Millions
Neuropace Inc	6.65	$ 98.620 Millions	$ 14.834 Millions
Aspira Women s Health inc	6.65	$ 9.029 Millions	$ 1.358 Millions
Bionano Genomics Inc	6.62	$ 30.176 Millions	$ 4.556 Millions
Liquidia Corporation	6.61	$ 450.907 Millions	$ 68.198 Millions
Pmgc Holdings Inc	6.57	$ 2.579 Millions	$ 0.393 Millions
Embecta Corp	6.50	$ 1,019.700 Millions	$ 156.775 Millions
Moderna Inc	6.49	$ 2,228.000 Millions	$ 343.250 Millions
Adaptive Biotechnologies Corporation	6.38	$ 308.081 Millions	$ 48.254 Millions
Iradimed Corporation	6.38	$ 86.339 Millions	$ 13.533 Millions
Edap Tms Sa	6.34	$ 111.051 Millions	$ 17.522 Millions
Syndax Pharmaceuticals Inc	6.32	$ 252.004 Millions	$ 39.902 Millions
Nuwellis Inc	6.28	$ 9.013 Millions	$ 1.435 Millions
Absci Corp	6.24	$ 1.561 Millions	$ 0.250 Millions
Maxcyte inc	6.22	$ 31.051 Millions	$ 4.994 Millions
Cue Biopharma Inc	6.21	$ 37.654 Millions	$ 6.064 Millions
Heartflow Inc	6.20	$ 210.791 Millions	$ 33.999 Millions
Omada Health Inc	6.20	$ 308.445 Millions	$ 49.770 Millions
Vertex Pharmaceuticals Inc	6.19	$ 12,587.200 Millions	$ 2,032.400 Millions
Integra Lifesciences Holdings Corp	6.14	$ 1,647.666 Millions	$ 268.153 Millions
Interpace Biosciences Inc	6.12	$ 36.519 Millions	$ 5.963 Millions
Treace Medical Concepts Inc	6.12	$ 205.307 Millions	$ 33.551 Millions

Date modified: 2026-09-03T12:16:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.